Taiwan and UK deepen medical policy exchange, promote provisional payment for innovative therapies
Taiwan and the UK have renewed their medical policy cooperation agreement, with the National Health Insurance Administration (NHIA) and NICE focusing on strengthening reimbursement for innovative medical technologies and establishing evaluation frameworks for gene and cell therapies.
📋 Article Processing Timeline
- 📰 Published: May 13, 2026 at 15:38
- 🔍 Collected: May 13, 2026 at 16:02 (23 min after Published)
- 🤖 AI Analyzed: May 14, 2026 at 03:10 (11h 8m after Collected)
Central News Agency
(Central News Agency reporter Chen Jie-ling, Taipei, 13th) The National Health Insurance Administration (NHIA) of the Ministry of Health and Welfare and the UK's National Institute for Health and Care Excellence (NICE) have renewed their cooperation agreement to deepen Taiwan-UK medical policy cooperation. This 3-year cooperation project includes strengthening reimbursement systems for innovative medical technologies, refining provisional payments, and establishing evaluation frameworks for innovative therapies such as gene and cell therapies.
The National Health Insurance Administration and the Center for Drug Evaluation (CDE) renewed their cooperation agreement with the UK's National Institute for Health and Care Excellence (NICE) on May 11, launching a new phase of Taiwan-UK health technology assessment cooperation. This will combine the legislation for Taiwan's National Health Technology Assessment Center as an administrative法人 to comprehensively promote an innovative health technology assessment framework.
The NHIA explained in a press release today that following the first signing with NICE in May 2023, this cooperation agreement was renewed by NHIA Director-General Chen Liang-yu under the witness of Minister of Health and Welfare Shih Chung-liang, planning cooperation priorities from 2026 to 2028, focusing on four major policy axes.
The NHIA stated that the first point is to "strengthen the evaluation and reimbursement system for innovative medical technologies," refining provisional payments and re-evaluation systems for gene and cell therapies to effectively manage long-term medical benefit uncertainties.
The second point is "sharing experience in cancer digital governance." The NHIA said that both parties will share how to promote the international standard format FHIR (Fast Healthcare Interoperability Resources) through the digital transformation of cancer treatment to accelerate pre-approval and establish a dynamic evaluation mechanism for the real-world benefits of cancer treatment.
The third point is to "cultivate professional talent and deepen international cooperation." The NHIA stated that through education and training, expert exchanges, and information network cooperation, Taiwan's Health Technology Assessment (HTA) professional capabilities will continue to be enhanced. The fourth point is to "incorporate social perspectives," strengthening the integration of medical, long-term care, and social care resources and policy evaluation capabilities.
Chen Liang-yu stated that through continued cooperation with NICE, a top international HTA institution, Taiwan will further strengthen the integration of its National Health Insurance health technology assessment, reimbursement system, and medical information digitalization, improve the efficiency of medical data governance, and promote the rational allocation of medical resources to ensure the sustainable development of the National Health Insurance system. (Edited by Chen Ching-fang) 1150513
Choose to stand with facts, every sponsorship you provide is a force for safeguarding press freedom.
Download the Central News Agency's "First-hand News" APP to stay updated with the latest news.
The text, images, and audio-visual content on this website may not be reproduced, publicly broadcast, publicly transmitted, or utilized without authorization.
(Central News Agency reporter Chen Jie-ling, Taipei, 13th) The National Health Insurance Administration (NHIA) of the Ministry of Health and Welfare and the UK's National Institute for Health and Care Excellence (NICE) have renewed their cooperation agreement to deepen Taiwan-UK medical policy cooperation. This 3-year cooperation project includes strengthening reimbursement systems for innovative medical technologies, refining provisional payments, and establishing evaluation frameworks for innovative therapies such as gene and cell therapies.
The National Health Insurance Administration and the Center for Drug Evaluation (CDE) renewed their cooperation agreement with the UK's National Institute for Health and Care Excellence (NICE) on May 11, launching a new phase of Taiwan-UK health technology assessment cooperation. This will combine the legislation for Taiwan's National Health Technology Assessment Center as an administrative法人 to comprehensively promote an innovative health technology assessment framework.
The NHIA explained in a press release today that following the first signing with NICE in May 2023, this cooperation agreement was renewed by NHIA Director-General Chen Liang-yu under the witness of Minister of Health and Welfare Shih Chung-liang, planning cooperation priorities from 2026 to 2028, focusing on four major policy axes.
The NHIA stated that the first point is to "strengthen the evaluation and reimbursement system for innovative medical technologies," refining provisional payments and re-evaluation systems for gene and cell therapies to effectively manage long-term medical benefit uncertainties.
The second point is "sharing experience in cancer digital governance." The NHIA said that both parties will share how to promote the international standard format FHIR (Fast Healthcare Interoperability Resources) through the digital transformation of cancer treatment to accelerate pre-approval and establish a dynamic evaluation mechanism for the real-world benefits of cancer treatment.
The third point is to "cultivate professional talent and deepen international cooperation." The NHIA stated that through education and training, expert exchanges, and information network cooperation, Taiwan's Health Technology Assessment (HTA) professional capabilities will continue to be enhanced. The fourth point is to "incorporate social perspectives," strengthening the integration of medical, long-term care, and social care resources and policy evaluation capabilities.
Chen Liang-yu stated that through continued cooperation with NICE, a top international HTA institution, Taiwan will further strengthen the integration of its National Health Insurance health technology assessment, reimbursement system, and medical information digitalization, improve the efficiency of medical data governance, and promote the rational allocation of medical resources to ensure the sustainable development of the National Health Insurance system. (Edited by Chen Ching-fang) 1150513
Choose to stand with facts, every sponsorship you provide is a force for safeguarding press freedom.
Download the Central News Agency's "First-hand News" APP to stay updated with the latest news.
The text, images, and audio-visual content on this website may not be reproduced, publicly broadcast, publicly transmitted, or utilized without authorization.